// STATE LEGISLATION TRACKER

Pennsylvania HB 1740: An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, in public safety, providing for

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Pennsylvania
Bill: HB 1740
Filed: 2019-08-16
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HB1740 would have required opioid treatment agreements before prescribing opioid controlled substances for chronic pain. It does not appear to regulate peptides, compounded peptides, off-label peptide use, telehealth peptide care, naturopathic or NP scope, or FDA 503A/503B compounding.

Key Points

No direct change to peptide prescribing or peptide access
Applies to opioid controlled substances for chronic pain, not typical peptides
Would add consent, education, and drug-testing expectations for opioid care
No apparent change to telehealth rules or clinician scope for peptide care
No apparent change to 503A or 503B peptide compounding

What to Watch For

Note This is an opioid-prescribing bill, so peptide users would usually not be affected.

Concern Clinics that also manage chronic pain opioids could face more paperwork and testing steps.

Note No clear impact on PDMP use beyond the broader controlled-substance context.

Where the Bill Stands

HB1740 was referred to the House Health Committee on August 16, 2019 and did not pass before the 2019-2020 session ended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws